Mateon Therapeutics, Inc.
701 Gateway Blvd., Suite 210
South San Francisco, California 94080
June 25, 2018
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3561
Washington, D.C. 20549
Re: | Mateon Therapeutics, Inc. |
Registration Statement on Form S-1
Filed on June 13, 2018
File No. 333- 225600
Acceleration Request
Ladies and Gentleman:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Mateon Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Tuesday, June 26, 2018, at 5:00 p.m. EST, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Any questions should be addressed to Megan N. Gates, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111, telephone (617) 348-4443.
Very truly yours, |
Mateon Therapeutics, Inc. |
/s/ Matthew M. Loar |
Matthew M. Loar |
Chief Financial Officer |
cc: | Securities and Exchange Commission |
Jeffrey Gabor |
Mateon Therapeutics, Inc. |
William D. Schwieterman, M.D., Chief Executive Officer |
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
Megan N. Gates, Esq. |
Melanie Ruthrauff Levy, Esq. |
Jenna M. Stewart, Esq. |